← Back to Search

Chemotherapy

Iodine-131 Anti-B1 Antibody for Non-Hodgkin's Lymphoma

Phase 2
Waitlist Available
Research Sponsored by Corixa Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have a histologically confirmed initial diagnosis of de novo diffuse large B-cell NHL according to the REAL classification
Patients must have had Ann Arbor, stage III or stage IV, or bulky Stage II disease at diagnosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test if using Iodine-131 Anti-B1 Antibody is safe and effective for treating patients with large B-cell non-Hodgkin's lymphoma who have responded to CHOP therapy.

Who is the study for?
This trial is for people under 80 with large B-cell non-Hodgkin's lymphoma who responded to CHOP therapy. They must have CD20 antigen, good performance status, and adequate organ function. Exclusions include other cancers within 5 years (except certain cases), HIV, prior treatments beyond CHOP, serious heart disease or illness, active infections requiring IV drugs, and pregnancy.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of Iodine-131 Anti-B1 Antibody in patients with large B-cell non-Hodgkin's lymphoma who've had a positive response after completing CHOP chemotherapy cycles.See study design
What are the potential side effects?
Potential side effects may include reactions related to iodine or the antibody such as allergic responses or thyroid issues. As it involves radioactive material, there might be risks associated with radiation exposure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My initial diagnosis was for a specific type of large B-cell lymphoma.
Select...
My cancer was diagnosed at a late or advanced stage.
Select...
My bone marrow involvement by NHL is less than 25%.
Select...
I've completed 6+ cycles of CHOP chemotherapy and saw improvement or remission.
Select...
My tumor tests positive for the CD20 protein.
Select...
I am 80 years old or younger.
Select...
I can care for myself and expect to live at least 3 more months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Corixa CorporationLead Sponsor
9 Previous Clinical Trials
590 Total Patients Enrolled

Media Library

CHOP (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00022932 — Phase 2
Non-Hodgkin's Lymphoma Research Study Groups:
Non-Hodgkin's Lymphoma Clinical Trial 2023: CHOP Highlights & Side Effects. Trial Name: NCT00022932 — Phase 2
CHOP (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00022932 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial open to participants below the age of twenty?

"This trial seeks participants aged 18 to 80. On the other hand, there are 321 studies available for minors and 1615 clinical trials accessible to those over 65 years of age."

Answered by AI

Are there vacancies in this experiment that volunteers can participate in?

"The data hosted on clinicaltrials.gov indicates that this medical trial has ended recruitment and is not accepting new participants at present. Initially posted in 2000, the last update was made in 2005. Despite this study's closure, there are an abundance of other trials actively recruiting patients today."

Answered by AI

To what degree does this treatment pose a health risk to individuals?

"Our internal assessment at Power determined that the safety of this treatment is likely a 2, as there exist some data regarding its safeguard but not enough to determine efficacy."

Answered by AI
~14 spots leftby Mar 2025